Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs MobilEye Global Inc (MBLY) Price & Performance

Eli Lilly And CoTrade
MobilEye Global IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs MobilEye Global Inc — how do they compare? Eli Lilly And Co trades at $1,222.99 (market cap $1.08T), while MobilEye Global Inc trades at $8.77 (market cap $7.54B). The key difference: Eli Lilly And Co is far larger — about 143.2× MobilEye Global Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.

LLYMBLY
Market Cap
$1.08T$7.54B
Sector
HealthTechnology
52-Week High
$1.24K$15.54
52-Week Low
$639.43$6.56
Enterprise Value
$1.13T$6.10B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

MobilEye Global Inc

Mobileye Global Inc. (MBLY) trades at $8.77, up 0.23% on the day, with a bullish technical signal driven by moving averages. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $0.19 surpassing expectations, but faces fundamental challenges with a net income margin of -201.49% in 2026. Recent news highlights CEO transition and expanded partnerships, such as the Stellantis ADAS supply deal announced July 21, 2026.

The outlook is mixed: analyst consensus is bullish with a $11.40 price target (61.54% buy ratings), but high valuation (EV/EBITDA 43.25) and profitability risks persist. Investment opportunity lies in autonomous driving growth, while key risks include leadership uncertainty and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About MobilEye Global Inc

Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.

Read more on MBLY